DNA methylation-mediated repression of microRNA-410 promotes the growth of human glioma cells and triggers cell apoptosis through its interaction with STAT3.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 01 2024
18 01 2024
Historique:
received:
20
06
2023
accepted:
11
01
2024
medline:
19
1
2024
pubmed:
19
1
2024
entrez:
18
1
2024
Statut:
epublish
Résumé
This study's purpose was to confirm the observed underexpression of miRNA-410 in glioma tissues and several glioma cells by Quantitative RT-PCR. Our findings suggest that epigenetic alterations occurring at the promoter region of miR-410 may be responsible for the reduced expression of miR-410 in glioma. The occurrence of DNA methylation in the miR-410 promoter was verified to be more prevalent through glioma tissues contrasted to adjacent non-tumor brain tissues through the utilization of methylation-specific PCR and CpG bisulfite sequencing sites in the miR-410 promoter region. Accordantly, miR-410 expression in glioma cell lines was observed to be significantly lesser in comparison to that of the human fetal glial cell line. In addition, it was demonstrated through gain- and loss-of-function investigations that miR-410 exerts significant regulation over cell growth, cell cycle development, and glioma cell apoptosis. The findings of the Luciferase reporter assay and western blot analysis indicate that miR-410 has a direct effect on the 3'-UTR of signal transducer and activator of transcription 3 (STAT3), thereby inhibiting its expression within glioma cells. Besides, our clinical investigation indicates a negative association between miR-410 expression and STAT3 within the glioma tissues of humans. In aggregate, the data provided in this investigation indicates that miR-410 is subjected to underexpression via DNA methylation. Furthermore, it has been observed to perform its function as a tumor suppressor in glioma cells through direct targeting of STAT3. The previously mentioned results could potentially have significant implications for the advancement of a new therapeutic approach for treating glioma.
Identifiants
pubmed: 38238515
doi: 10.1038/s41598-024-51976-x
pii: 10.1038/s41598-024-51976-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1556Subventions
Organisme : Natural Science Foundation of China
ID : 81960910
Organisme : Self-funded project of Guangxi Health Commission
ID : Z20210130
Informations de copyright
© 2024. The Author(s).
Références
Liang, S. P. et al. Activated SIRT1 contributes to DPT-induced glioma cell parthanatos by upregulation of NOX2 and NAT10. Acta Pharmacol. Sin. https://doi.org/10.1038/s41401-023-01109-3 (2023).
doi: 10.1038/s41401-023-01109-3
pubmed: 38110583
pmcid: 10462642
Boulhen, C. et al. TMIGD2 as a potential therapeutic target in glioma patients. Front Immunol. 14, 1173518. https://doi.org/10.3389/fimmu.2023.1173518 (2023).
doi: 10.3389/fimmu.2023.1173518
pubmed: 37261362
pmcid: 10227580
Andrews, L. J., Davies, P., Herbert, C. & Kurian, K. M. Pre-diagnostic blood biomarkers for adult glioma. Front Oncol. 13, 1163289. https://doi.org/10.3389/fonc.2023.1163289 (2023).
doi: 10.3389/fonc.2023.1163289
pubmed: 37265788
pmcid: 10229864
Seo, M. et al. Glioma grading using multiparametric MRI: head-to-head comparison among dynamic susceptibility contrast, dynamic contrast-enhancement, diffusion-weighted images, and MR spectroscopy. Eur. J. Radiol. 165, 110888. https://doi.org/10.1016/j.ejrad.2023.110888 (2023).
doi: 10.1016/j.ejrad.2023.110888
pubmed: 37257338
Anvari, K., Shahabadi, M., Welsh, J. S., Javadinia, S. A. & Zarei, E. Outcome of second line treatment of recurrent high- grade glioma by re-irradiation or bevacizumab-based chemotherapy: A cross sectional study. Asian Pac. J. Cancer Prev. 24, 1507–1511. https://doi.org/10.31557/APJCP.2023.24.5.1507 (2023).
doi: 10.31557/APJCP.2023.24.5.1507
pubmed: 37247269
pmcid: 10495891
Meng, Q., Yang, P. & Lu, Y. MicroRNA-410 serves as a candidate biomarker in hypoxic-ischemic encephalopathy newborns and provides neuroprotection in oxygen-glucose deprivation-injured PC12 and SH-SY5Y cells. Brain Behav. 11, e2293. https://doi.org/10.1002/brb3.2293 (2021).
doi: 10.1002/brb3.2293
pubmed: 34331407
pmcid: 8413830
Nan, S., Wang, Y., Xu, C. & Wang, H. Interfering microRNA-410 attenuates atherosclerosis via the HDAC1/KLF5/IKBalpha/NF-kappaB axis. Mol. Ther. Nucleic Acids 24, 646–657. https://doi.org/10.1016/j.omtn.2021.03.009 (2021).
doi: 10.1016/j.omtn.2021.03.009
pubmed: 33981482
pmcid: 8076652
Zhang, H., Ding, W., Ji, F. & Wu, D. MicroRNA-410 participates in the pathological process of postmenopausal osteoporosis by downregulating bone morphogenetic protein-2. Exp. Ther. Med. 18, 3659–3666. https://doi.org/10.3892/etm.2019.7996 (2019).
doi: 10.3892/etm.2019.7996
pubmed: 31602244
pmcid: 6777323
Yin, Y. et al. Correction to: Upregulating MicroRNA-410 or downregulating Wnt-11 increases osteoblasts and reduces osteoclasts to alleviate osteonecrosis of the femoral head. Nanoscale Res. Lett. 16, 43. https://doi.org/10.1186/s11671-020-03465-z (2021).
doi: 10.1186/s11671-020-03465-z
pubmed: 33687586
pmcid: 7943676
Deshpande, R. P., Chandra Sekhar, Y., Panigrahi, M. & Babu, P. P. SIRP Alpha Protein Downregulates in Human Astrocytoma: Presumptive Involvement of Hsa-miR-520d-5p and Hsa-miR-520d-3p. Mol. Neurobiol. 54, 8162–8169. https://doi.org/10.1007/s12035-016-0302-8 (2017).
doi: 10.1007/s12035-016-0302-8
pubmed: 27900675
Ma, Z. H., Shi, P. D. & Wan, B. S. MiR-410-3p activates the NF-kappaB pathway by targeting ZCCHC10 to promote migration, invasion and EMT of colorectal cancer. Cytokine 140, 155433. https://doi.org/10.1016/j.cyto.2021.155433 (2021).
doi: 10.1016/j.cyto.2021.155433
pubmed: 33517196
Yuan, Y. et al. miR-410 induces both epithelial-mesenchymal transition and radioresistance through activation of the PI3K/mTOR pathway in non-small cell lung cancer. Signal Transduct. Target Ther. 5, 85. https://doi.org/10.1038/s41392-020-0182-2 (2020).
doi: 10.1038/s41392-020-0182-2
pubmed: 32528035
pmcid: 7290026
Liu, Z. et al. Expression of miR-410 in peripheral blood of patients with clear cell renal cell carcinoma and its effect on proliferation and invasion of Caki-2 cells. J. BUON 26, 2059–2066 (2021).
pubmed: 34761617
Lu, Y. T. et al. Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314. Eur. Urol. Oncol. https://doi.org/10.1016/j.euo.2023.03.008 (2023).
doi: 10.1016/j.euo.2023.03.008
pubmed: 38143206
Hu, S. et al. Accurate detection of early-stage lung cancer using a panel of circulating cell-free DNA methylation biomarkers. Biomark Res. 11, 45. https://doi.org/10.1186/s40364-023-00486-5 (2023).
doi: 10.1186/s40364-023-00486-5
pubmed: 37101220
pmcid: 10134678
Song, K. & Artibani, M. The role of DNA methylation in ovarian cancer chemoresistance: A narrative review. Health Sci. Rep. 6, e1235. https://doi.org/10.1002/hsr2.1235 (2023).
doi: 10.1002/hsr2.1235
pubmed: 37123549
pmcid: 10140645
Choi, J. M., Park, C. & Chae, H. meth-SemiCancer: A cancer subtype classification framework via semi-supervised learning utilizing DNA methylation profiles. BMC Bioinform. 24, 168. https://doi.org/10.1186/s12859-023-05272-6 (2023).
doi: 10.1186/s12859-023-05272-6
Acuna, S. M., Zanatta, J. M., de Almeida Bento, C., Floeter-Winter, L. M. & Muxel, S. M. miR-294 and miR-410 Negatively Regulate Tnfa, Arginine Transporter Cat1/2, and Nos2 mRNAs in Murine Macrophages Infected with Leishmania amazonensis. Noncoding RNA https://doi.org/10.3390/ncrna8010017 (2022).
doi: 10.3390/ncrna8010017
pubmed: 35202090
pmcid: 8875753
Boyineni, J. et al. SPARC overexpression combined with radiation retards angiogenesis by suppressing VEGF-A via miR-410 in human neuroblastoma cells. Int. J. Oncol. 49, 1394–1406. https://doi.org/10.3892/ijo.2016.3646 (2016).
doi: 10.3892/ijo.2016.3646
pubmed: 27498840
pmcid: 5021251
Liu, D. et al. MiR-410 down-regulates the expression of interleukin-10 by targeting STAT3 in the pathogenesis of systemic lupus erythematosus. Cell Physiol. Biochem. 39, 303–315. https://doi.org/10.1159/000445625 (2016).
doi: 10.1159/000445625
pubmed: 27351906
Wu, C. Y. et al. 2,3,7,8-tetrachlorodibenzo-p-dioxin promotes proliferation of astrocyte cells via the Akt/STAT3/Cyclin D1 pathway. Biomed. Environ. Sci. 32, 281–290. https://doi.org/10.3967/bes2019.038 (2019).
doi: 10.3967/bes2019.038
pubmed: 31217064
Wang, F., Cao, X. Y., Lin, G. Q., Tian, P. & Gao, D. Novel inhibitors of the STAT3 signaling pathway: An updated patent review (2014-present). Expert Opin. Ther. Pat. 32, 667–688. https://doi.org/10.1080/13543776.2022.2056013 (2022).
doi: 10.1080/13543776.2022.2056013
pubmed: 35313119
Jiang, D. et al. Retracted: Long chain non-coding RNA (lncRNA) HOTAIR knockdown increases miR-454-3p to suppress gastric cancer growth by targeting STAT3/Cyclin D1. Med. Sci. Monit. 29, e939464. https://doi.org/10.12659/MSM.939464 (2023).
doi: 10.12659/MSM.939464
pubmed: 36628645
pmcid: 9844008
Okabe, N. et al. STAT3 activation in thymic epithelial tumors: Correlation with cyclin D1, JAK3, and clinical behavior. Gen. Thorac. Cardiovasc Surg. 69, 1482–1491. https://doi.org/10.1007/s11748-021-01655-9 (2021).
doi: 10.1007/s11748-021-01655-9
pubmed: 34061303
Chen, L. et al. MiR-410 regulates MET to influence the proliferation and invasion of glioma. Int. J. Biochem. Cell Biol. 44, 1711–1717. https://doi.org/10.1016/j.biocel.2012.06.027 (2012).
doi: 10.1016/j.biocel.2012.06.027
pubmed: 22750473